Dysregulated RNA splicing drives cellular senescence
PrimarySenisca's core causal theory is that dysregulated RNA splicing is a druggable hallmark of ageing that contributes to the senescent-cell state. If age-associated disruption of mRNA processing causes or maintains senescence, then restoring more youthful splicing patterns should reduce senescent-cell phenotypes and thereby affect age-related disease processes. Testable predictions include: senescent or aged cells should show reproducible splicing-factor or alternative-splicing abnormalities; correcting those abnormalities should reduce senescence markers or senescence-associated secretory phenotypes; and tissues treated through this mechanism should show improved function in age-related disease or ageing-related contexts.
Popperian evaluation
The premise is credible: ageing and senescence are linked to altered mRNA processing, and oligonucleotide tools can in principle change splicing. The weaker part is causality. The supplied evidence supports age-associated splicing disruption and senomorphic intent, but it does not yet prove that these splicing changes sit upstream of senescence rather than arriving after broader cell stress has already done the damage.
Supporting evidence: The theory predicts reproducible splicing-factor or alternative-splicing abnormalities in senescent or aged cells, and the evidence context rates this prediction high confidence.; The 2021 Senisca-linked and skincare senotherapeutic publications identify dysregulated mRNA processing as an ageing hallmark and discuss oligonucleotide manipulation as a senomorphic strategy.; The mechanism is biologically specific: restore youthful splicing patterns, then test senescence markers, SASP, and tissue function.
Counter evidence: The key assumption remains only medium confidence: age-associated splicing changes may be downstream correlates of senescence rather than drivers or maintainers.; The publication set supplied here is thin and includes review-level support, with no abstract for the most directly relevant Senisca paper.; The PBMC immune-age study supports functional ageing in older cells, but it does not directly test splicing correction.
The theory explains a real slice of the evidence: aged or senescent cells can show splicing disruption, and correcting that disruption could plausibly reduce senescent phenotypes. But it does not yet beat simpler alternatives. DNA damage, mitochondrial stress, chronic inflammation, epigenetic drift, and cell-cycle arrest could all produce both senescence and altered splicing. Right now, splicing is a plausible causal node, not the proven driver.
Supporting evidence: The reasoning chain links disrupted mRNA processing to senescence markers, SASP, and age-related tissue function.; The evidence context includes a direct prediction that correcting splicing abnormalities should reduce senescence markers or SASP, rated high confidence.; Reviews cited in the dossier discuss dysregulated mRNA processing as a hallmark that can be targeted for senomorphic effects.
Counter evidence: The strongest alternative explanation is correlation: senescent cells may have abnormal splicing because they are senescent, not because splicing caused the state.; The supplied evidence does not show that splicing correction outperforms other senescence-targeting mechanisms.; The tissue-function prediction is only medium confidence, which is the right level of caution because cell-marker rescue does not automatically mean organ-level benefit.
This theory is quite testable. It makes concrete predictions at three levels: aged cells should show reproducible splicing abnormalities, targeted correction should reduce senescence markers or SASP, and treated tissues should function better in ageing-related models. A clean failure at the second step would hurt the theory badly: if splicing is corrected but p16, p21, SA-beta-gal, SASP factors, or relevant functional readouts do not move, the causal claim loses its teeth.
Supporting evidence: The theory specifies measurable molecular predictions: splicing-factor changes and alternative-splicing abnormalities.; It specifies intervention tests: correcting splicing abnormalities should reduce senescence markers or SASP.; It extends to functional tests in tissues, which creates a harder endpoint than marker movement alone.
Counter evidence: The phrase 'restoring youthful splicing patterns' needs operational thresholds before a decisive test can be scored.; Senescence has multiple marker panels, so the theory could be weakened by selective endpoint choice unless assays are fixed in advance.; Tissue-level ageing contexts are broad; falsification is strongest if the model, cell type, splicing target, and functional endpoint are pre-specified.
Reasoning tree
Public endorsements
Ben Lee publicly ties himself to Senisca's core splicing theory on Senisca's own site. He says he joined Lorna Harries's team shortly after their discovery that mRNA splicing played a fundamental role in the ageing process, then helped found Senisca as CTO. That is stronger than a passing mention: it is a direct public affirmation of the causal premise behind the company.
Evidence publication IDs: aeb864f4-8e05-42b7-b135-e6a38f956c3f, 5df83d39-b1c5-4702-9a4d-2970c9a721b5
The public evidence here ties Kirsty Semple to SENISCA as a co-founder and includes a CEO quote about investment and cell rejuvenation, but none of it states or discusses the specific theory that dysregulated RNA splicing drives cellular senescence. On this record, she is publicly present around the company, but silent on that causal claim.
Professor Lorna Harries is publicly identified as SENISCA's co-founder and Chief Scientific Officer, and SENISCA's public scientific approach says its founders discovered that age-related changes in splicing factors are a fundamental reason cells become senescent and that restoring those factors can reverse senescence. That is the company's core theory in public, and Harries is presented as part of the scientific leadership behind it.
Evidence publication IDs: 158ef570-a5e9-4914-b326-c0eff1284db3, a07f6765-c45c-4de2-b258-3279b2a7f173
The dossier does not show any public statement from "Rejuvenated Senescent Fibroblasts" on Senisca's RNA-splicing theory. The records mention Senisca, Lorna Harries, and third-party commentary about targeting senescence through RNA splicing, but none are attributable to this named person or directly document their endorsement, contradiction, or even a neutral mention.